Physician profile
Mark G Loomus
NPI 1821198599
$6,312.00
in general payments reported to CMS, 2019-2025
38 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $728 · 2021: $523 · 2022: $783 · 2023: $1,308 · 2024: $975 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,742.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,118.36 | 2021-2025 | |
| Emd Serono, INC. | $722.32 | 2019-2025 | Mavenclad |
| Tg Therapeutics, INC. | $524.71 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $333.35 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $255.28 | 2019-2024 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $248.47 | 2019-2021 | |
| Genentech USA, INC. | $180.99 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Biogen, INC. | $180.24 | 2020-2025 | Vumerity, Tysabri |
| Genzyme Corporation | $177.57 | 2019-2020 | |
| Eisai INC. | $154.21 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $145.63 | 2019-2022 | |
| Sk Life Science, INC. | $135.29 | 2020-2023 | |
| Ucb, INC. | $133.74 | 2021-2024 | Rystiggo |
| Acadia Pharmaceuticals INC | $76.65 | 2020-2024 | Nuplazid |
| Impel Pharmaceuticals INC. | $75.37 | 2022-2023 | Trudhesa |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Loomus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.